Marizyme, Inc. is a biotechnology company, which engages in the acquisition, development, and commercialization of therapies that minimize mortality and costs in the acute care space. It offers DuraGraft, a one-time intraoperative vascular graft treatment that improves clinical outcomes by reducing the incidence and complications of graft failure, and Krillase, a patented protease-based therapeutic. The company was founded on March 20, 2007 and is headquartered in Jupiter, FL.
CEO： Mr. David Barthel
Market： Pink Market